SCHEMBL31172671

SCHEMBL31172671

COc1cc(C(=O)O)ccc1Cn1cccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.56
AGTR1 P30556 1/20 0.51
AGTR2 P50052 1/20 0.51
TSHR P16473 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
TPMT P51580 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
KLKB1 P03952 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
GAA P10253 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
HDAC6 Q9UBN7 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172762 1.00 HTT (0.56) HTTAGTR1AGTR2TSHRCA12
SCHEMBL4354266 0.90 HTT (0.56) HTTTSHRCA12CA1CA2
SCHEMBL553315 0.89 KLKB1 (0.47) HTTTSHRKLKB1MEN1KMT2A
SCHEMBL31172710 0.89 MAPK1 (0.49) HTTAGTR1AGTR2KLKB1MEN1
SCHEMBL31172603 0.89 MAPK1 (0.49) HTTAGTR1AGTR2KLKB1MEN1
SCHEMBL31172703 0.84 HTT (0.53) HTTAGTR1AGTR2HDAC6HDAC1
SCHEMBL31172670 0.84 HTT (0.53) HTTAGTR1AGTR2TSHRKLKB1
SCHEMBL31691458 0.84 HTT (0.55) HTTAGTR1AGTR2TSHRKLKB1
SCHEMBL31172672 0.83 KAT7 (0.42) HTTKLKB1MEN1KMT2ANPSR1
SCHEMBL553252 0.83 KLKB1 (0.63) HTTKLKB1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 508/4885AGTR1 2360/4885AGTR2 2611/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B HTT 508/4885AGTR1 2360/4885AGTR2 2611/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 1323/4885AGTR1 397/4885AGTR2 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.